2015年12月17日星期四
Fuda Cancer Hospital is the first privately owned specialty hospital in Guangzhou accredited by the JCI
Fuda Cancer Hospital, based in Guangzhou, China, received a notice issued by the JCI headquarters on its gaining JCI accreditation, making it the 31st hospital in China that meets the standards designed by the world’s most stringent international hospital evaluation system.
Surveyors arriving at Fuda Cancer Hospital
Fuda Cancer Hospital embarked on the JCI accreditation journey in 2011. In the course of the past 2 years, all staff of Fuda Cancer Hospital worked closely together under correct hospital leadership and conducted every aspect of work following the JCI philosophy “To continuously improve the safety and quality of patient care”. From March 17 to 2014, Fuda Cancer Hospital received official inspections by JCI accreditation surveyors. And the hospital was eventually awarded the decision of Accreditation.
Survey opening conference and photograph taking
Winning JCI accreditation is a significant milestone in the development of Fuda Cancer hospital and marks a new starting point for the hospital. The hospital will incorporate the principle of continuously improving patient safety and care quality into its daily work, therefore enabling better delivery of higher-quality professional medical services for patients from at home and abroad under the precondition of safety assurance.
Morning meeting
The JCI headquarters notified Fuda of winning JCI accreditation and expressed congratulations. In his congratulation, the surveyor mentioned “Many thanks to your excellent team for giving me an opportunity to be educated and learn”.
Surveyors visiting the nurse station
It is reported that a total of 31 medical institutions have gained JCI accreditation in China. Of the 31 organizations, six are located in Guangdong province, with four in Guangzhou and two in Shenzhen. Fuda Cancer Hospital is the first privately owned specialty hospital in Guangzhou accredited by the JCI. There are over 1200 JCI measurable elements. If a hospital has more than 40 items that fail to meet the specified requirements, the accreditation is denied to the hospital.
Facility tour and document review
Leadership session
Exit conference
Submission of the evaluation report
Submission of the evaluation report
Leadership session
Exit conference
Submission of the evaluation report
Submission of the evaluation report
Successful completion of inspections
2015年12月16日星期三
The First Nano Knife (irreversible electroporation) Treatment for Cancer in Mainland of China Completed in Guangzhou
In the morning of July 1, 2015, a special operation was undergoing in the operation room of Guangzhou Fuda Cancer Hospital. The patient lying on the operation table was a 61-year-old man from Middle East. With the assistance of renowned abdominal surgeon--Prof. Li Chaolong, Dr. Niu Lizhi cut open the patient’s upper abdominal with adept skill, separated stomach and intestinal canal to expose pancreas. A 4.5x5.0cm large quasi circular mass is found. Dr. Niu put the ultrasonic surgical probe on the mass and an uneven high- density echo displayed on the ultrasound screen. Under the guidance of ultrasound image, Dr. Niu placed a special electrode needle (called main needle) into one side of the mass and inserted its tip to the bottom of the mass; then two auxiliary electrode needles were inserted into the other side and the center of the mass separately. The three needles formed a tripod shape with the distance between each standing at 2cm.
Beside the operating table, an engineer was adjusting the medical equipment called “NanoKnife.” On the screen displayed flashing electric pulse, which meant that the equipment was at operational readiness. Beneath the NanoKnife was a special electrocardiogram equipment, which displayed the patient’s cardiac rhythm.
The treatment started. Dr. Niu ordered: electric shock. According to the premeditated plan, three groups of electric shocks with 1500V voltage and 70 microseconds pulse length are administered with 90 pulses in each group. With the pulses pushing in, the ultrasound screen displayed that the original high-density echo of the tumor was getting lower.
After the above-mentioned procedures were done, Dr. Niu changed the position of two auxiliary electrode needles and electric pulses were administered again. Then, three electrode needles were pulled up and electric pulses were administered again. After repeating the process for five times, the tumor had fully received electric pulses. The CT scan (contrast agent enhancement) on the second day showed whole tumor necrosis.
This is a memorable moment. On this day, FUDA succeed in treating pancreatic cancer by adopting the world’s latest ablation technology--irreversible electroporation for the first time in Guangzhou, also in China. The technology got its name “Nano Knife” because it would make nanoscale membrane perforation in targeted tissue or cells.
As a significant progress in tumor treatment of the 21st century, tumor ablation has presented an effective treatment and even radical chance for patients with unresectable tumor or patients who cannot tolerate operation. The most frequently used technologies include thermal ablation (radio-frequency and microray) and cryoablation (Argon-Helium Knife and liquid nitrogen). Nano Knife is a special ablation technology belonging to neither thermal ablation nor cryoablation. If ablation could be compared to the “crown “of local treatment for cancer, then Nano Knife could be compared to the “pearl” on the “crown”. The basic rationale of Nano Knife is that ablation probes release microsecond high voltage pulse that breaks tumor cell membrane so as to form nanoscale irreversible electroporation and finally kill targeted cells (cancer cells).
A series of experiments and clinical research indicate that compared with other ablation technologies, Nano Knife has the following unique advantages: the ablation of tissue is selective. The ablation destroys only cells and does no harm to vascular wall, nerve, trachea, bronchus, gallbladder, intestinal canal, and ureter; boundaries of ablation area is clear, which is extremely important for small volume pancreas; ablation does not generate energy nor rely on it, and it is not influenced by the blood flow of adjacent big vessels, such as celiac artery and aorta; the death of cells is not necrosis but apoptosis, which could stimulate anticancer immune responses; the ablation requires short treatment time. It just takes 5 minutes to ablate 3.0 cm large tumor and anesthesia time will also shorten accordingly, which is conducive to postoperative recovery. The ablation process can be clearly displayed on ultrasound, CT or MR, thus ensuring the maximal effect of ablation.
Developed and manufactured by America AngiDymanics company, Nano Knife was approved by America FDA for “soft tissue tumor ablation”, which was hailed by experts around the world. European Union, Australia, Canada has also successively approved Nano Knife for application. As of today, over 100 key tumor hospitals have adopted this technology in treating more than 6,000 cases. Treated tumors are located in pancreas, lungs, kidney, prostate, and other parenchymal organs as well as in soft tissues. It is especially applicable to tumors near big vessels, hepatic hilum, gallbladder, bile ducts, and ureter. According to literature, Nano Knife is of great value in treating pancreatic cancer.
Nano Knife can not only be applied to surgery, such as laparotomy. Electrodes needles can also be inserted into tumor through puncture point and percutaneous ablation can be administered under the guidance of CT or ultrasound. In recent days, under the guidance of CT and ultrasound, doctors in FUDA have carried out percutaneous Nano Knife ablation on a postoperative gastric cancer metastasis and a pancreatic head tumor.
In June, 2015, China approved Nano Knife for tumor treatment. In order to apply Nano Knife into clinical treatment in an early date, one year before it is approved by China, Dr. Niu Lizhi has led experts and relevant medical workers to study stacks of literature and arranged several study tours in America. They compiled the first monograph about Nano Knife in China, New Technique of Cancer Ablation: Irreversible Electroporation published by Shanghai Science and Technology Literature in 2014. In cooperation with overseas institutions, experts and medical workers in FUDA carried out a large number of Nano Knife ablation experiments on animals, studied its influence and safety on such key structures as nerves, vessels, bile ducts and ureter and published the first paper about Nano Knife in China on Journal of Interventional Radiology.
Beside the operating table, an engineer was adjusting the medical equipment called “NanoKnife.” On the screen displayed flashing electric pulse, which meant that the equipment was at operational readiness. Beneath the NanoKnife was a special electrocardiogram equipment, which displayed the patient’s cardiac rhythm.
During operation
The treatment started. Dr. Niu ordered: electric shock. According to the premeditated plan, three groups of electric shocks with 1500V voltage and 70 microseconds pulse length are administered with 90 pulses in each group. With the pulses pushing in, the ultrasound screen displayed that the original high-density echo of the tumor was getting lower.
After the above-mentioned procedures were done, Dr. Niu changed the position of two auxiliary electrode needles and electric pulses were administered again. Then, three electrode needles were pulled up and electric pulses were administered again. After repeating the process for five times, the tumor had fully received electric pulses. The CT scan (contrast agent enhancement) on the second day showed whole tumor necrosis.
This is a memorable moment. On this day, FUDA succeed in treating pancreatic cancer by adopting the world’s latest ablation technology--irreversible electroporation for the first time in Guangzhou, also in China. The technology got its name “Nano Knife” because it would make nanoscale membrane perforation in targeted tissue or cells.
As a significant progress in tumor treatment of the 21st century, tumor ablation has presented an effective treatment and even radical chance for patients with unresectable tumor or patients who cannot tolerate operation. The most frequently used technologies include thermal ablation (radio-frequency and microray) and cryoablation (Argon-Helium Knife and liquid nitrogen). Nano Knife is a special ablation technology belonging to neither thermal ablation nor cryoablation. If ablation could be compared to the “crown “of local treatment for cancer, then Nano Knife could be compared to the “pearl” on the “crown”. The basic rationale of Nano Knife is that ablation probes release microsecond high voltage pulse that breaks tumor cell membrane so as to form nanoscale irreversible electroporation and finally kill targeted cells (cancer cells).
Nano Knife electrode needles
A series of experiments and clinical research indicate that compared with other ablation technologies, Nano Knife has the following unique advantages: the ablation of tissue is selective. The ablation destroys only cells and does no harm to vascular wall, nerve, trachea, bronchus, gallbladder, intestinal canal, and ureter; boundaries of ablation area is clear, which is extremely important for small volume pancreas; ablation does not generate energy nor rely on it, and it is not influenced by the blood flow of adjacent big vessels, such as celiac artery and aorta; the death of cells is not necrosis but apoptosis, which could stimulate anticancer immune responses; the ablation requires short treatment time. It just takes 5 minutes to ablate 3.0 cm large tumor and anesthesia time will also shorten accordingly, which is conducive to postoperative recovery. The ablation process can be clearly displayed on ultrasound, CT or MR, thus ensuring the maximal effect of ablation.
Developed and manufactured by America AngiDymanics company, Nano Knife was approved by America FDA for “soft tissue tumor ablation”, which was hailed by experts around the world. European Union, Australia, Canada has also successively approved Nano Knife for application. As of today, over 100 key tumor hospitals have adopted this technology in treating more than 6,000 cases. Treated tumors are located in pancreas, lungs, kidney, prostate, and other parenchymal organs as well as in soft tissues. It is especially applicable to tumors near big vessels, hepatic hilum, gallbladder, bile ducts, and ureter. According to literature, Nano Knife is of great value in treating pancreatic cancer.
Nano Knife can not only be applied to surgery, such as laparotomy. Electrodes needles can also be inserted into tumor through puncture point and percutaneous ablation can be administered under the guidance of CT or ultrasound. In recent days, under the guidance of CT and ultrasound, doctors in FUDA have carried out percutaneous Nano Knife ablation on a postoperative gastric cancer metastasis and a pancreatic head tumor.
In June, 2015, China approved Nano Knife for tumor treatment. In order to apply Nano Knife into clinical treatment in an early date, one year before it is approved by China, Dr. Niu Lizhi has led experts and relevant medical workers to study stacks of literature and arranged several study tours in America. They compiled the first monograph about Nano Knife in China, New Technique of Cancer Ablation: Irreversible Electroporation published by Shanghai Science and Technology Literature in 2014. In cooperation with overseas institutions, experts and medical workers in FUDA carried out a large number of Nano Knife ablation experiments on animals, studied its influence and safety on such key structures as nerves, vessels, bile ducts and ureter and published the first paper about Nano Knife in China on Journal of Interventional Radiology.
Before Treatment
After Treatment
2015年12月13日星期日
2015年12月2日星期三
Niu Lizhi from Guangdong, China Being Elected as the Only Vice Chairman of International Society of Cryosurgery (ISC)
The 18th World Congress of International Society of Cryosurgery was held in Kanazawa, Japan from November 25 to November 27, 2015. Over 200 representatives from dozens of countries including America, England, Japan, Russia and China attended the congress with over 80 papers presented. Representatives from Chinese PLA General Hospital, Fuda Cancer Hospital, Sun Yat-sen University Cancer Center, The First Hospital of Sun Yat-sen University, Cancer Research Institute of Shandong University, the Second People’s Hospital of Shenzhen, and Cancer Research Institute of Fudan University delivered speeches on the congress.
Three experts, namely Prof. Korpan from Austria, Prof. Xu Kecheng from China and Prof. Sumida from Japan were specially invited to deliver keynote speeches. Prof. Xu Kecheng from Guangzhou, China illustrated the application of cryosurgery in cancer treatment, including radical cure of early stage tumor, reduction of tumor load, cryosurgery-assisted resection and pain alleviation. He laid emphasis on the application of NanoKnife therapy for pancreatic cancer. He proposed that the combination of cryosurgery and NanoKnife therapy is the best approach for tumor ablation at present.
On the Congress, the council of ISC smoothly completed the general election. On the closing ceremony, Prof. Xu Kecheng, President of 18th World Congress of ISC and President of the 17th council of ISC handed over the flag and seal of the society to Prof. Isoda from Nagoya University. The new Council was established in the warm applause from all representatives. Prof. Isoda was elected as President of ISC while Prof. Niu Lizhi from Guangzhou Fuda Cancer Hospital was elected as the only Vice President of the ISC.
The new Council of ISC consists of 21 representatives from America, England, Japan, Russia and etc., among which there are 6 members from China, including Prof. Xiao Yueyong from Chinese PLA General Hospital, Prof. Li Wentao from Cancer Research Institute of Fudan University, Prof. Xu Kecheng and Prof. Niu Lizhi from Fuda Cancer Hospital, Prof. Zhao Zhenlin from the Second People’s Hospital of Shenzhen, and Prof. Li Dinggang from Beijing Daopei Hospital. Representatives from China and Japan hold the most seats of the Council.
Prof. Korpan from Austria, honorary President of ISC presented the Special Award of Cryosurgery for Cancer as a token of recognition of his tremendous contribution in developing world cryosurgery medicine and cryosurgery treatment.
Prof. Xu Kecheng, on behalf of the 17th Council presented the trophy and bonus to those who have made great achievement in the field of cancer cryosurgery. Prof. Tsuchiya from Kanazawa University, Japan won the Gold Award, Prof. Li Jiaping from Sun Yat-sen University, China the Silver Award and Doctor Yaron from Israel the Bronze Award.
The International Society of Cryosurgery has gone through 43 years since its initiation in 1972. In 2007, over 100 Chinese representatives attended the 14th World Congress of ISC held in Beijing. The 14th World Congress started with the report delivered by Prof. Zhang Jiren who firstly introduced Argon-Helium cryosurgery from America. The report covered the status quo of cryosurgery in China. Over 10,000 cases of patients have received cryosurgery, among which Fuda Cancer Hospital has done the most cases (over 2,000 cases) mainly on liver cancer and pancreatic cancer; PLA Navy General Hospital went the second with over 1,000 cases mainly on lung cancer. The treatment experience of the two hospitals above attracted the attention of all representatives. Prof. Xu Kecheng and Dr. Niu Lizhi from Fuda Cancer Hospital, Prof. Feng Huasong from PLA Navy General Hospital, Prof. Qian Guojun from Shanghai Eastern Hepatobiliary Hospital won Special Contribution Award for Cryosurgery on the Congress.
In 2009, the 15th World Congress of ISC was held in St. Petersburg, Russia. The first special topic was “the best Cryosurgery Center in the World”, during which Fuda Cancer Hospital of China and Mayo Clinic from America were invited to make speeches. The topic of the second day is “Cryosurgery for Pancreatic Cancer at FUDA” with an emphasis on introducing FUDA’s taking a lead in carrying out cryosurgery for pancreatic cancer.
In 2011, the 16th World Congress of ISC was held in Vienna, Austria. A Chinese delegation with 32 experts led by Prof. Xu Kecheng from China attended the Congress. Xu Kecheng, Xiao Yueyong, Niu Lizhi were elected as the executive member of the Council. Xu Kecheng was elected as Vice President of ISC. Xu Kecheng, Niu Lizhi, Chen Jibing, Wang Hongwu and Xiao Yueyong from China won awards.
In 2012, Xu Kecheng and Prof. Sumida initiated to establish the Asian Society of Cryosurgery with registration in Hongkong and the legal chairman of the Society as Prof. Xu Kecheng. The Society set up a council which was firstly headed by Prof. Xiao Yueyong.
In the same year, Modern Cryosurgery for Cancer (English Edition) co-edited by Xu Kecheng, Korpan, Niu Lizhi was published by World Scientific Press and released across the world. The monograph has been collected by Libraries of University of Oxford and National Library of America. As of now, the first edition has been sold out and the second edition is about to release.
In 2013, the 17th World Congress of ISC was held in Bali, Indonesia. Prof. Xu Kecheng from China was elected as President of ISC. In the past two years, ISC has hosted three international forums on cancer in Guangzhou and Shenzhen with a focus on cryosurgery for cancer, cryo-immunity and immunotherapy and etc, which has attracted the attention of experts from many countries around the world.
China has made remarkable achievement in the field of cryosurgery, which has attracted the world’s attention. On the 18th World Congress of the ISC, Dr. Javorsky from Massachusetts General Hospital of Medical School of Harvard University believed that “China has undoubtedly reached the world’s highest level in terms of practice and experience in cryosurgery for cancer.”
订阅：
博文 (Atom)